Clinical-stage biotechnology company (NASDAQ: LGVN)
Appears in 1 story
Strategic review after failed Phase 2b trial
Longeveron's stem cell therapy for a rare pediatric heart disease missed the main goal of its mid-stage trial, and the Miami biotech is now fighting to stay alive. With about $10.1 million in cash at the end of June, the company announced a strategic review and cost-cutting plan.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
